Moroccan drug prices are too high and cost-containment measures are needed following the extension of the compulsory health system.

Following the publication of a Parliamentary report in November 2009, which found that drug prices were too high in Morocco, even in comparison to Tunisia, the government has launched a new regulation to bring pharmaceutical prices down and encourage generics consumption. The new system limits the number of generic medicaments to 14, by International Common Denomination (ICD), and only one generic per manufacturer. One of the main measures is that the new pricing system introduces international benchmarking criteria. Another measure is the regular review of pharmaceutical prices. Contrary to the actual system, pharmaceutical prices will no longer be fixed.

The national health insurance scheme is expected to provide substantial additional funding for the health sector. Initially aimed at salaried workers, the scheme has been expanded to cover the self-employed. The CNSS, which operates the scheme in the private sector, has announced that it will be extending cover to ambulatory care in addition to hospital treatment from February 2010 onwards. A health insurance scheme for those on very low incomes is still in the early stages of implementation and is expected to be rolled out on a national basis in 2010. Full implementation of national health insurance will require cost-containment measures due to increasing reimbursement levels.

All the posts in the World Pharmaceutical Markets category have been written by the WPM team at Espicom Business Intelligence please click here to purchase the detailed 64 page report on The Pharmaceutical Market Morocco

Related articles by Zemanta

Tagged with: • • • • • • • • • • • • • • •

Filed under: World Pharmaceutical Markets

Like this post? Subscribe to my RSS feed and get loads more!